In 1974 we reported the transient appearance of an unexpected mouse allotype (1) . An antigen indistinguishable from the BALB/c IgG2~ allotype (Ig-la) l was detected in a congenic partner strain of BALB/c (C.B-17). However, C.B-17 mice were bred to exclude Ig-la and were typed homozygous for the gene that controls production of the IgG2a allotype of C57BL/Ka mice (Ig-lb). Because Ig-la was normally undetectable in C.B-17 mice, we referred to it as a hidden allotype (Ig-la').
Other investigators have also noted nonallelic behavior of Ig allotypes. Lobb (2) and Rivat et al. (3) reported that human blood lymphocytes stimulated with phytohemagglutinin, or in mixed lymphocyte cultures, produce Gm allotypes not found in the serum of the donor, although it should be added that other laboratories (4, 5) have not been able to confirm this work. Pothier (6) observed that Syrian hamsters injected with human lymphoid tumors produce human allotype markers; one such recipient animal was briefly positive for Gm (a) and Gm (z), even though the injected cells came from a Gm (a-) donor. For rabbits, too, there are examples in which allotypes not anticipated from genetic data have been detected. Strosberg et al. (7) first noted the appearance of three group a allotypes and three group b allotypes in a rabbit immunized against Micrococcus lysodeickticus. Mudgett et al. (8) followed with the observation that normal rabbits of the as allotype sometimes show small quantities of al and a3 in their serum (--<1% of the as concentration). Further, the examination of over 119 rabbits showed that very low concentrations of al, as, or a3 allotypes could be found in rabbits of all nominal alloytpe combinations. Such hidden or latent allotypes appeared transiently in microgram quantities (per milliliter of serum) in -~50% of the rabbits examined (8) . Latent rabbit allotypes for both variable and constant regions have now been observed in several laboratories (9, 10, 1 1).
All of the preceding serological observations are difficult to interpret because antiallotype sera are likely to contain subspecificities of antibody directed against different allotypic determinants. This is illustrated for rabbit allotypes by the findings of van der Loo et al. (12) and Mage et al. (13) ; namely, that anti-as made in a3a3, but not in alaa or ata3 rabbits, can see as-like determinants in hyperimmunized ala3 rabbits. This means that it is critical to distinguish whether a hidden allotype is in fact a leaky * Supported by U. S. Public Health Service grants AI-13323, CA-04946, CA-06927, and RR-05539 from the National Institutes of Health; and by an appropriation from the Commonwealth of Pennsylvania.
Abbreviations used in this paper: BSA, bovine serum albumin; CH, heavy-chain-constant; C. (11) have recently applied more stringent assays to measure latent a allotypes; they conclude that detection of such antigens cannot be attributed to weak cross-reactions or to technical artifact.
Relevant to the above, we have used a radioimmune assay to analyze the Ig-la' found in two pooled serum samples from different Igb-congenic BALB/c strains, one from C.B-17, and the other from BAB/14 mice. We report direct measurements of competitive and noncompetitive binding of Ig-la' to specifically purified anti-Ig-la. Our results indicate that Ig-la' and Ig-la are serologically identical.
Materials and Methods
Mouse-Strain AUotypes. Ig allotypes of BALB/c (Iga) and C57BL (Ig b) are noted according to the nomenclature of Herzenberg et al. (14) . Of particular interest is the IgG2a allotype of BALB/c (Ig-la) because an antigen indistinguishable from Ig-la (Ig-la') was detected in certain 7S Ig preparations of BAB/14 and C.B-17 pooled mouse sera. As allotype-congenic partners of BALB/c mice, the latter two strains were made homozy~ous after 14 and 17 backcross generations for C57BL/Ka genes that control production of Ig allotypes (i.e., Ig-lb, Ig-2b, etc.) Radiolabeling of 7S Ig. The labeling of 7S Ig (220 gg) with 131I or 125I was according to the chloramine T method of Hunter (16) . This was done in sealed V-shaped vials containing 2 mCi of isotope (New England Nuclear, Boston, Mass.). To remove unreacted isotope and small radiodamaged protein products, each preparation was passed over a column of Sephadex G-50 (1 X 35 cm, Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) topped by a mixed bed (2 cm) of ion-exchange resin (Amberlite IR 4B, Mallinckrodt Inc., St. Louis, Mo.; and Bio-Rad AG, 1 X 8 cm, Bio-Rad Laboratories, Richmond, Calif.). The resulting preparations showed specific activities ranging from 8 to 12 × 106 cpm/#g protein.
7S Ig Preparations.

Radioimmune Assay
CONSTRUCTION OF IC-IA-REACTlVE WELLS. Microtiter wells (Cooke Engineering Co., Alexandria, Va.) were made specifically Ig-la-reactive by a procedure described elsewhere (17) . This entailed successive additions, incubations, and washings as indicated: (a) 50 gI of 0.01% bovine serum albumin (BSA) containing 1 gg of Ig-la or Ig-la Ig-la' was done at 4°C in a reaction vol of 50 btl; 16 h later, the wells were washed, cut out, and counted.
By using different labeled forms of both competitors ([12sI]Ig-la and [131I]Ig-la'), direct measurements of their binding could be made. For this, increasing concentrations of each were mixed together and added in 50-~1 vol to Ig-la-reactive wells. shown (A). The remaining two preparations (C, E) were not inhibitory in this assay; neither were 7S Ig preparations of B6, C57BL/Ka, or Fab fragments of M173. Additional controls to show that specificity of this assay system is restricted to Ig-la have been reported elsewhere (17, 18) .
Results
Detection of Ig-la' in 7S Ig
Noncompetitive Binding of [125I]Ig-la' and [1251]Ig-la to Ig-la-Reactive Wells. A direct
estimate of the quantity of Ig-la' in preparation A of Fig. 1 was made as follows. Limiting dilutions of [125]I-A were added to Ig-la-reactive wells. As anti-Ig-la was in excess, the percentage of [12s]I-A bound was independent of the amount added. Table  I shows representative results of five such experiments. As can be seen, 0.1-0.3% of [12~]I-A was bound, which is consistent with a quantitative interpretation of the results in Fig. 1 . With the same kind of procedure, the percentage of Ig-i a in 7S Ig of BALB/ c and in preparations of M173, U10, and LPC-1 was estimated; the values were 24, 58, 64, and 91% respectively (not shown).
Competitive Binding of [ta:I]Ig-la ' and [12sI]Ig-la to Ig-la-Reactive Wells. To examine
whether the affinity of anti-Ig-la for Ig-la' was comparable to its affinity for Ig-la, we labeled preparation A (of Fig. 1 ) with a31I ([131I]Ig-la') and the Ig-la myeloma protein of U10 with 125I ([t25I]Ig-la). The simultaneous addition of both labeled antigens to Ig-la-reactive wells enabled us to measure their binding under conditions in which each would have to compete with the other. The quantity of reactive [131I]Ig-la' and [125I]Ig-la added was determined by noncompetitive assays (of the kind shown in Table I ) that were carried out in parallel to the above. Ig-la' is that of preparation A of Fig. 1 and [125I]Ig-la is that of U10 myeloma protein. Table II 
Discussion
The preceding results showed that certain pools of C.B-17 (and BAB/14) serum contained detectable Ig-la'. This antigen was indistinguishable from reference Ig-la proteins and represented -0.1-0.3% of the 7S serum Ig fraction. Consistent with our previous observations (1), Ig-la' production appeared to be transient, as not all 7S Ig preparations of C.B-17 and BAB-14 mice had detectable Ig-la'. The following is a discussion of (a) the basis for considering Ig-la' identical to Ig-la, and (b) explanations for low, transient productions of Ig-1 a'.
Evidence that Ig-la' Is Equivalent to Ig-la. The first question to consider is whether detection of Ig-la' could be an experimental artifact relating to nonspecific binding or to Ig-la-like crossreacting determinants. Evidence against this idea is as follows: (a) The assay for Ig-la' was highly specific, it utilized specifically purified anti-Ig-la and homogenous Ig-la myeloma proteins; (b) Ig-la' did not act as an incomplete competitor as is typical of cross-reacting protein antigens, rather it could displace completely the binding of [~25I]Ig-la to Ig-la-reactive wells (Fig. 1) ; (c) The bound fraction of Ig-la' represented 0.1-0.3% of the 7S Ig added (preparation A). This compared favorably with its effectiveness as a competitor; i.e., to get comparable inhibition of the binding of [125I]Ig-la to Ig-la-reactive wells, it was necessary to add -1,000-fold more 7S Ig of preparation A than Ig-la myeloma protein (Fig. 1) ; and (d) Direct measurements of competitive binding of [laaI]Ig-la' and [125I]Ig-la to Ig-lareactive wells showed these two antigens to be indistinguishable.
Possible Explanations for Low, Transient Production of Ig-l a'
DEFICIENT EXPRESSION AND STIMULATION OF IG-IA' B CELLS.
The presence of Ig-la' in Ig-lb-producing C.B-17 mice could result from leaky expression of a normally silent Ig-la' locus. Manifestation of this at the cellular level could be low and variable numbers of Ig-la'-bearing B cells.
It seems possible that heavy-chain-constant (CH) region genes for Ig-la' and Ig-lb may be expressed with different heavy-chain-variable (VH) genes. If this were not so and members of the same set of VH genes were to randomly join with either CH gene, we would expect to see early and regular production of both Ig-la' and Ig-lb. That this does not occur with Ig-la' could reflect its association with a small and distinct set of VH regions (Ig-la' locus). Serum Ig-la' would then go undetected unless the appropriate antigens were present to induce sufficient clonal proliferation of the few Ig-la'-bearing cells.
The possibility that the putative Ig-la' locus might contain additional CH genes is suggested by our preliminary radioimmune evidence for Ig-4a' in pools A and D of Fig. 1 (our unpublished data) (Ig-4a corresponds to BALB/c IgG1). This prompts us to speculate as before (18) that the mouse genome may contain several disjoint clusters of VH, CH and allelic regulator (RH) genes. The expression of a given gene cluster would then depend on which RH allele is active.
THYMUS-DEPENDENT SUPPRESSION OF IG-IA t B CELLS.
Not mutually exclusive of the preceding considerations, C.B-17 mice might generate thymus-dependent immunity against Ig-la'-producing B cells. Unless such B cells were to appear early and regularly in the developing C.B-17 mouse, the host might be intolerant of their presence.
Suggestive evidence for possible involvement ofcytotoxic or suppressor T cells (Tcs cells) in Ig-la' regulation comes from recent experiments. Earlier, we reported (18) that normal allotype-congenic mice appear to contain T cells that can prevent adoptively transferred lymphocytes of allotype-congenic partner mice from producing their respective allotypes. The strength of such allotype barriers varies according to the allotypes in question. In the case of C.B-17 vs. BALB/c, the barrier is relatively weak. That is, after transfer of BALB/c lymphocytes to C.B-17 hosts, donor Ig-la appears and then disappears in many recipients. This does not happen when cells of the same donor are transferred to nude C.B-17 mice. In all nude recipients, donor Igla persists for as long as such mice have been tested (>10 wk after cell transfer) (18, and our unpublished observations). Thus, specific Tcs in normal C.B-17 mice may prevent Ig-la' B cells from producing Ig-la'. Such Tcs cells could serve as a primary or secondary regulatory system for maintaining the silence of Ig-la'. It is not clear what structures on Ig-la' B cells would be seen as foreign, although they would presumably be controlled by allotype-linked genes.
From the data presented and cited, it seems certain that hidden mouse allotypes do in fact exist, but that specific regulatory mechanisms normally prevent their production. Regulation is likely to involve both intra-and extracellular mechanisms. To understand the latter will require identification of specific recognition elements and their controlling genes in a given regualtory network of lymphocytes. Table II NONCOMPETITIVE BINDING OF IG-IA AND IG-IA t TO IG-tA-REACTIVE WELLS.
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